Myrcludex B: Phase Ib/IIa started

Hepatera began an open-label, Russian Phase Ib/IIa trial to compare 0.5, 1 and 2 mg subcutaneous Myrcludex B daily for 12 weeks vs. Baraclude entecavir in about 32 hepatitis B e antigen (HBeAg)-negat...